
Is It Better to Shower in the Morning or at Night?
You might step into the shower every morning because it helps wake you up, or you might take a shower at night to wash the day away.
But scientific evidence supporting one type of shower over the other is limited. It really just comes down to preference.
Health and wellness touch everyone's lives differently. The views and opinions expressed are those of the speakers and do not necessarily reflect the views or positions of Healthline Media. All quotes are strictly informational and should not be considered medical advice.
Does it matter what time you shower?
You don't need to align your shower with a certain time of day for health benefits. Either, depending on your preferences, can be good for you.
Benefits of a morning shower
You may find that you benefit from a morning shower if you:
Need a morning pick-me-up: Not everyone rises in the morning feeling ready to go. If this sounds like you, a warm (not hot) shower may help. You might also want to try turning the water to cold for a moment as an extra wake-up call.
Want to start the day fresh and clean: Your bed contains sweat, skin cells, and skin oils, and showering in the morning sends this residue that you might have picked up overnight down the drain.
Style your hair: If you wake up with unruly hair, you're not alone. A morning shower can help reset your hair, especially if you use hair products that call for application on wet hair.
Benefits of a night shower
However, if going to bed clean rather than starting the day clean is more your style, you may benefit from a night shower.
Some benefits of showering in the evening may include:
Removing a day's worth of dirt: Your skin picks up bacteria and grime whenever it comes in contact with something or someone. Showering at night stops this gunk and other topical skin care products you might apply throughout the day from getting into bed with you.
Cleaner sheets: If you go to bed clean, you won't have to worry about your sheets getting dirty as fast. But your sheets will still inevitably get dirty over time.
Night showers
go to bed clean
cleaner sheets
potentially better sleep
Showering tips (no matter the timing)
Consider some of these pointers the next time you shower for potentially even more benefits:
Use warm water: Hot water (above 104°F [40°C]) may feel good, but it's more likely to dry out your skin and aggravate inflammatory skin conditions, like psoriasis or eczema. A hot shower may also raise already high blood pressure.
Add a blast of cold water at the end: Though it might not sound the most pleasant, a dose of cold water may help promote healthy skin and hair, increase circulation, and wake you up (if needed).
Use gentle soaps and cleansers: Opt for gentle body washes instead of harsh scrubs and heavily scented products, especially if you live with an inflammatory skin condition or have sensitive skin.
Limit your showers to 5 to 10 minutes: A long, hot shower at the end of the day may sound relaxing, but according to the American Academy of Dermatology, try to limit your showers to between 5 and 10 minutes, especially if you have dry skin or an inflammatory skin condition.
Pat your skin dry: After your shower, try not to rub your skin, as this can dry it out and damage its moisture barrier, which is what helps your skin hold onto moisture. Instead, gently pat it dry.
Follow up with a moisturizer: To lock in moisture, try applying a gentle moisturizer within a few minutes of toweling off.
Be sure to connect with a healthcare professional if you live with an inflammatory skin condition, have chronic dry skin, or another skin disorder before changing your shower habits.
We polled some of our staff to help get a better sense of where the Healthline team stands on this conundrum. See the results below and what some of them have to say.
'I grew up in Asia, where everyone takes at least one shower, and the one at night is nonnegotiable. The reason? You don't want to bring all the sweat and dirt to your clean bed. I guess it also helps reduce the need for frequent washing of the bed sheets.' — Louisa Wah, editor
'I need [a morning shower] to clear the fog and get my day started. Some of my most productive work ideas happen during that time!' — Heidi Smith, Real Appeal manager
'I think of showers as a way to wash away the day and help my mind reset for bedtime. I also really don't like getting into bed with the dirt of the day still on me.' — Megan Severs, senior editorial director
'I work out and walk my dog in the evening, so it fits better in my schedule to shower at night and wash away the sweat and grime from being outside! Plus, there is nothing like getting into a clean bed after a hot shower :)' — Victoria Torrez, senior influencer marketing manager
'I need to be clean before I get into bed! Plus, it has become part of my nighttime routine and helps my brain recognize that things are winding down.' — Sara McTigue, senior editor, Bezzy
'I feel very strongly about [night showers]. I have a 'shower lamp' that has very soft lighting, and my showers are steaming hot, so I'll fall asleep if I do them in the morning. I also want to be clean before I get in bed. It doesn't sit right with me having everything built up from the day get on my sheets, especially if I worked out or spent a long time outside.' — Sarah Choi, associate editor
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Genentech and Roche Present New Insights in Alzheimer's Disease Research Across Its Diagnostics and Pharmaceutical Portfolios at AAIC
– Trontinemab's Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative and ARIA-E remaining <5% – – Design of the Phase III TRONTIER 1 and 2 studies of trontinemab in early symptomatic Alzheimer's disease featured, with initiation planned in 2025 – – Plans for new Phase III trial investigating trontinemab in preclinical Alzheimer's disease, in people at high risk of cognitive decline – – New real-world data support Elecsys pTau217 as a standalone blood test, comparable to a PET scan, for rule-in and rule-out identification of amyloid pathology – SOUTH SAN FRANCISCO, Calif., July 28, 2025--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer's development portfolio is being presented at the Alzheimer's Association International Conference (AAIC) in Toronto, Canada (July 27-30). These data exemplify the comprehensive approach Roche is taking in addressing Alzheimer's across the entire patient journey. Featured oral presentations include the latest results from the ongoing Phase Ib/IIa Brainshuttle™ AD study, which continue to support rapid and robust reduction of amyloid plaques, and design of the Phase III TRONTIER 1 and 2 studies of investigational trontinemab for early symptomatic Alzheimer's disease, with initiation planned later this year. As part of its growing Alzheimer's development program, Roche announced today its plans for an additional Phase III trial to investigate trontinemab in preclinical Alzheimer's disease. The trial will focus on individuals at risk of cognitive decline, with the goal of potentially delaying or preventing the progression of the disease to symptomatic stages. "Alzheimer's disease represents one of the greatest challenges in healthcare today and tackling it requires early detection and effective therapeutics," said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. "Trontinemab is designed to target a key driver of Alzheimer's disease biology more effectively in the brain. Combining new treatment avenues with advanced diagnostics may enable earlier and potentially more effective intervention. With plans for Phase III trials in both early symptomatic and preclinical Alzheimer's disease, we are advancing science with the goal of delaying—and ultimately preventing—progression of this devastating condition." Late-breaking oral and poster presentations highlight the potential of Roche's Elecsys® pTau217 as a reliable and accessible blood-based biomarker test, providing comparable results to PET scan and cerebrospinal fluid (CSF) diagnostics for rule-in and rule-out diagnosis of amyloid pathology, a hallmark of Alzheimer's disease, across care settings. The test, which received Breakthrough Device Designation from the U.S. Food and Drug Administration last year, will also be utilized in Roche's TRONTIER studies. "Blood based testing for Alzheimer's disease has the potential to greatly improve patient access and decrease the time to definitive disease diagnosis," said Matt Sause, CEO of Roche Diagnostics. "Our data show that the Elecsys pTau217 test performs comparably to PET scans but can be performed with a simple blood draw and analyzed in a routine clinical laboratory. This has the potential to transform the diagnosis of Alzheimer's and provide clear answers to caregivers, patients, and their families." Up to 75% of people living with symptoms of Alzheimer's disease globally have not been diagnosed, and those who have, waited an average of 2.8 years, and even less have received any form of treatment. Diagnostics play a crucial role in addressing the global challenge of Alzheimer's, not only to detect and identify people with the disease early, even before the first symptoms, but also to rule out those who may or may not benefit from specific treatments. Pharmaceuticals In a 90-minute Featured Research session, designs were shared for the Phase III studies, TRONTIER 1 and 2, which will initiate later this year, investigating the efficacy and safety of investigational trontinemab in people with early Alzheimer's disease. The primary endpoint will measure the change in cognition and function based on the Clinical Dementia Rating – Sum of Boxes scale after 18 months of treatment. Secondary endpoints will include assessments of cognition, function, behavioral symptoms, and quality of life. A pre-screening study, TRAVELLER, based on a brief clinical assessment and a plasma biomarker, which will be identified using the Elecsys pTau217 test, has also been initiated, to enable broader community outreach and extend access to these trials to more diverse populations representative of Alzheimer's disease. New data on the latest results for trontinemab from the completed dose-expansion part of the 1.8 mg/kg and 3.6 mg/kg cohorts from the ongoing Phase Ib/IIa Brainshuttle AD study continued to show rapid and robust reduction of amyloid plaques in the brain as measured by amyloid positron emission tomography (PET). In the 3.6 mg/kg cohort, trontinemab reduced amyloid levels below the 24 centiloid positivity threshold in 91% of participants (n=49/54) after 28 weeks of treatment; 72% (n=39/54) achieved deep clearance below 11 centiloids. These data were reinforced by early and significant reductions in fluid biomarkers of Alzheimer's disease, including total tau, phosphorylated Tau (pTau)181, pTau217, and neurogranin measured in CSF and continues to show a favourable safety and tolerability profile. Amyloid-related imaging abnormalities-edema/effusion (ARIA-E) continued to be observed in <5% of participants (blinded data; N=4/149 across 1.8 and 3.6 mg/kg dose cohorts). All cases were radiographically mild, one was associated with mild and transient symptoms. Diagnostics Roche will present data on a new study comparing the pTau217/Ab42 plasma ratio to the high-throughput, fully automated Elecsys pTau217 assay. The presentation will report on the accuracy of these tools in detecting amyloid pathology. Together with the high throughput and full automation of the assay, these data will assess the potential of Elecsys pTau217 as an accurate standalone rule-in and rule-out test that could be scaled up for broad implementation in routine clinical practice worldwide. Additionally, results from a cohort-based model of healthcare utilization in the U.S. demonstrated that using the Elecsys® pTau181 blood-based rule-out test in primary care scenarios improved diagnostic accuracy and reduced resource use compared with the current standard-of-care clinical, cognitive and imaging tests. If made available in primary care settings, the Roche Elecsys® pTau181 blood test has the potential to reliably avoid the need for further confirmatory testing in nearly all people who receive a negative result. This will avoid the need for these people to undergo unnecessary testing using CSF or PET, which often come with long wait times and high cost, resulting in further delays to diagnosis and cost to healthcare systems. Medicine Abstract title Presentation number (type) Presentation date (session) Time Abstracts will be available on the AAIC website. Pharmaceuticals Next wave of innovation in Alzheimer's disease therapeutics: The value of novel active transport mechanisms Featured Research Session (FRS), Talk 1 Room 718 27 July 2025, 2pm - 3:30pm EDT Cath Mummery, Roberto Villaseñor, Jens Niewoehner, Scarlett Barker, Luka Kulic Latest results from the dose-expansion part (Part 2) of the Brainshuttle™ AD study of trontinemab in people with Alzheimer's disease Featured Research Session (FRS), Talk 2 Room 718 27 July 2025, 2pm - 3:30pm EDT Luka Kulic, Fabien Alcaraz, Gregory Klein, Stephen Salloway, Carsten Hofmann, João A. Abrantes, Stella Yilmaz, Denise Sickert, Maddalena Marchesi, Jakub Wojtowicz, Andres Schneider, Ruth Croney, David Agnew, Silke Ahlers, Paul Delmar, Hanno Svoboda, Iris Wiesel Interim biomarker results for trontinemab, a novel Brainshuttle™ antibody in development for the treatment of Alzheimer's disease Featured Research Session (FRS), Talk 3 Room 718 27 July 2025, 2pm - 3:30pm EDT Gregory Klein, Gil Rabinovici, Henrik Zetterberg, Matteo Tonietto, Tobias Bittner, Daria Rukina, Fabien Alcaraz, Carsten Hofmann, Maddalena Marchesi, Jakub Wojtowicz, Ruth Croney, David Agnew, João A. Abrantes, Franziska Schaedeli Stark, Silke Ahlers, Paul Delmar, Hanno Svoboda, Iris Wiesel, Luka Kulic TRONTIER 1 and TRONTIER 2: Pivotal trials of trontinemab in early symptomatic Alzheimer's disease Featured Research Session (FRS), Talk 4 Room 718 27 July 2025, 2pm - 3:30pm EDT Janice Smith, Catherine Mummery, Jeffrey L. Cummings, Gil Rabinovici, Stephen Salloway, Reisa Sperling, Henrik Zetterberg, Angeliki Thanasopolou, Christopher Lane, Paul Delmar, Gregory Klein, Ruth Croney, Jakub Wojtowicz, Carsten Hofmann, Luka Kulic, Hideki Garren Diagnostics Evaluating the Impact on Diagnostic Performance and Healthcare Resource Utilization of Introducing a plasma rule-out test in the Alzheimer's Disease Diagnostic Pathway Poster #102729 27 July 2025, 7:30am - 4:15pm EDT Sophie Roth, Gustaf Ortsäter, Joana Amorim Freire Location tbc Evaluating the Clinical Performance of the Elecsys pTau217 Plasma Immunoassay to Detect Amyloid Pathology in a Routine Clinical Practice Cohort Poster #96679 28 July 2025, 7:30am – 4:15pm EDT Sayuri Hortsch, Niels Borlinghaus, Alexander Jethwa, David Caley, Annunziata Di Domenico, Craig Ritchie Clinical performance and effect of pre-analytical variation of plasma pTau217 alone versus the plasma pTau217/Aβ42 ratio for the identification of amyloid pathology Oral Developing Topics #108585 3-23-DEV Developing Topics on Tau Biomarkers 29 July 2025, 2:00pm – 3:30pm EDT Christopher M. Rank, Joana Amorim Freire, Alexander Jethwa, Annunziata Di Domenico, Christina Rabe, Marc Suárez-Calvet, Colin L. Masters, Tobias Bittner Accuracy of cerebrospinal fluid biomarker ratios to determine amyloid positron-emission tomography status: a diagnostic test accuracy meta-analysis Poster #100941 28 July 2025, 7:30am – 4:15pm EDT Pablo Martinez-Lage, Eino Solje, Julian G. Martins, Sraboni Sarkar Equity in diagnosis through adequate clinical trial design in diagnostic performance studies Poster #102804 30 July 2025, 7:30am - 4:15pm EDT Imke Kirste, David Caley, Clara Quijano Rubio, Margherita Carboni Investigating Differences in Patients Enrolled in a Clinical Study Based on Referral Type Poster #108110 30 July 2025, 7:30am - 4:15pm EDT Sophie Roth, Laura Schlieker, Sayuri Hortsch, Joana Amorim Freire, David Caley About trontinemab Trontinemab is an investigational Brainshuttle bispecific 2+1 amyloid-beta targeting monoclonal antibody specifically engineered for enhanced access to the brain to enable rapid reduction of amyloid in people with Alzheimer's disease. Trontinemab is designed for the efficient transport across the blood-brain barrier to target aggregated forms of amyloid beta and remove amyloid plaques in the brain. The uniqueness of trontinemab is based on Roche's proprietary Brainshuttle technology combining an amyloid beta-binding antibody with a transferring receptor (TfR1) shuttle module. As a result, high central nervous system (CNS) exposure of trontinemab may be achieved at low doses, leading to a rapid and deep amyloid clearance. Due to its unique properties, trontinemab might unlock the full potential of disease-modifying monoclonal antibodies by effectively penetrating the brain and potentially leading to slowing of disease progression. About Roche in Alzheimer's Disease With more than two decades of scientific research in Alzheimer's disease, Roche is working towards a day when we can detect and treat the disease early, in order to slow down, stop or even prevent its progression to preserve what makes people who they are. Today, the company's Alzheimer's disease portfolio spans investigational medicines for different targets, types and stages of the disease, including trontinemab. On the diagnostics side, it also includes approved and investigational tools, including digital and blood-based tests and CSF assays, aiming to more effectively detect, diagnose and monitor the disease. Yet the global challenges of Alzheimer's disease go well beyond the capabilities of science, and making a meaningful impact requires collaboration both within the Alzheimer's community and outside of healthcare. Roche will continue to work together with numerous partners with the hope to transform millions of lives. About Genentech in Neuroscience Neuroscience is a major focus of research and development at Genentech. Our goal is to pursue groundbreaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases. Genentech and Roche are investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer's disease, Huntington's disease, Parkinson's disease and Duchenne muscular dystrophy. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today. About Genentech Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit View source version on Contacts Media Contact: Meghan Hindman (650) 467-6800Advocacy Contact: Jenee Williams (650) 303-2958Investor Contacts: Loren Kalm (650) 225-3217Bruno Eschli +41616875284 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
32 minutes ago
- Yahoo
Arizona Lottery Pick 3, Fantasy 5 results for July 27, 2025
The Arizona Lottery offers multiple draw games for those aiming to win big. Arizona offers Powerball, Mega Millions, The Pick, Triple Twist, Fantasy 5 and Pick 3 as well as Scratchers, Quick Draw and Fast Play. Lottery players have seen enormous jackpots recently, with previous winners of both the Powerball and Mega Millions breaking into the top 10 largest jackpots in U.S. lottery history. Money raised from Arizona lottery games goes toward funding higher education, health and human services, environmental conservation and economic and business development in the state. Pick 3 5-5-0 Check Pick 3 payouts and previous drawings here. Fantasy 5 05-16-18-23-33 Check Fantasy 5 payouts and previous drawings here. Triple Twist 11-13-15-27-39-42 Check Triple Twist payouts and previous drawings here. Feeling lucky? Explore the latest lottery news and results Are you a winner? Here's how to claim your lottery prize All Arizona Lottery retailers will redeem prizes up to $100 and may redeem winnings up to $599. For prizes over $599, winners can submit winning tickets through the mail or in person at Arizona Lottery offices. By mail, send a winner claim form, winning lottery ticket and a copy of a government-issued ID to P.O. Box 2913, Phoenix, AZ 85062. To submit in person, sign the back of your ticket, fill out a winner claim form and deliver the form, along with the ticket and government-issued ID to any of these locations: Phoenix Arizona Lottery Office: 4740 E. University Drive, Phoenix, AZ 85034, 480-921-4400. Hours: 7:30 a.m. to 5 p.m. Monday through Friday, closed holidays. This office can cash prizes of any amount. Tucson Arizona Lottery Office: 2955 E. Grant Road, Tucson, AZ 85716, 520-628-5107. Hours: 7:30 a.m. to 5 p.m. Monday through Friday, closed holidays. This office can cash prizes of any amount. Phoenix Sky Harbor Lottery Office: Terminal 4 Baggage Claim, 3400 E. Sky Harbor Blvd., Phoenix, AZ 85034, 480-921-4424. Hours: 8:30 a.m. to 5 p.m. Monday through Sunday, closed holidays. This office can cash prizes up to $49,999. Kingman Arizona Lottery Office: Inside Walmart, 3396 Stockton Hill Road, Kingman, AZ 86409, 928-753-8808. Hours: 8 a.m. to 8 p.m. Monday through Friday, 8:30 a.m. to 5 p.m. Saturday and Sunday, closed holidays. This office can cash prizes up to $49,999. Check previous winning numbers and payouts at Winning lottery numbers are sponsored by Jackpocket, the official digital lottery courier of the USA TODAY Network. Where can you buy Arizona lottery tickets? Tickets can be purchased in person at gas stations, convenience stores and grocery stores. Some airport terminals may also sell lottery tickets. You can also order tickets online through Jackpocket, the official digital lottery courier of the USA TODAY Network, in these U.S. states and territories: Arizona, Arkansas, Colorado, Idaho, Maine, Massachusetts, Minnesota, Montana, Nebraska, New Hampshire, New Jersey, New York, Ohio, Oregon, Puerto Rico, Washington D.C., and West Virginia. The Jackpocket app allows you to pick your lottery game and numbers, place your order, see your ticket and collect your winnings all using your phone or home computer. Jackpocket is the official digital lottery courier of the USA TODAY Network. Gannett may earn revenue for audience referrals to Jackpocket services. GAMBLING PROBLEM? CALL 1-800-GAMBLER, Call 877-8-HOPENY/text HOPENY (467369) (NY). 18+ (19+ in NE, 21+ in AZ). Physically present where Jackpocket operates. Jackpocket is not affiliated with any State Lottery. Eligibility Restrictions apply. Void where prohibited. Terms: This results page was generated automatically using information from TinBu and a template written and reviewed by an Arizona Republic editor. You can send feedback using this form. This article originally appeared on Arizona Republic: Arizona Lottery Pick 3, Fantasy 5 results for July 27, 2025 Solve the daily Crossword
Yahoo
32 minutes ago
- Yahoo
Idaho Lottery results: See winning numbers for Pick 3, Pick 4 on July 27, 2025
Looking to win big? The Idaho Lottery offers several games if you think it's your lucky day. Lottery players in Idaho can chose from popular national games like the Powerball and Mega Millions, which are available in the vast majority of states. Other games include Lotto America, Lucky For Life, 5 Star Draw, Idaho Cash, Pick 3 and Pick 4. Big lottery wins around the U.S. include a lucky lottery ticketholder in California who won a $1.27 billion Mega Millions jackpot in December 2024. See more big winners here. And if you do end up cashing a jackpot, here's what experts say to do first. Here's a look at Sunday, July 27, 2025 results for each game: Winning Pick 3 numbers from July 27 drawing Day: 0-4-8 Night: 4-6-8 Check Pick 3 payouts and previous drawings here. Winning Pick 4 numbers from July 27 drawing Day: 9-8-3-6 Night: 0-3-4-4 Check Pick 4 payouts and previous drawings here. Winning Lucky For Life numbers from July 27 drawing 04-06-09-25-47, Lucky Ball: 04 Check Lucky For Life payouts and previous drawings here. Winning Idaho Cash numbers from July 27 drawing 03-12-18-21-30 Check Idaho Cash payouts and previous drawings here. Feeling lucky? Explore the latest lottery news & results When are the Idaho Lottery drawings held ? Powerball: 8:59 p.m. MT Monday, Wednesday and Saturday. Mega Millions: 9 p.m. MT on Tuesday and Friday. Pick 3: 1:59 p.m. (Day) and 7:59 p.m. (Night) MT daily. Pick 4: 1:59 p.m. (Day) and 7:59 p.m. (Night) MT daily. Lucky For Life: 8:35 p.m. MT Monday and Thursday. Lotto America: 9 p.m. MT on Monday, Wednesday and Saturday. 5 Star Draw: 8 p.m. MT on Tuesday and Friday. Idaho Cash: 8 p.m. MT daily. Winning lottery numbers are sponsored by Jackpocket, the official digital lottery courier of the USA TODAY Network. Where can you buy lottery tickets? Tickets can be purchased in person at gas stations, convenience stores and grocery stores. Some airport terminals may also sell lottery tickets. You can also order tickets online through Jackpocket, the official digital lottery courier of the USA TODAY Network, in these U.S. states and territories: Arizona, Arkansas, Colorado, Idaho, Maine, Massachusetts, Minnesota, Montana, Nebraska, New Hampshire, New Jersey, New York, Ohio, Oregon, Puerto Rico, Washington D.C., and West Virginia. The Jackpocket app allows you to pick your lottery game and numbers, place your order, see your ticket and collect your winnings all using your phone or home computer. Jackpocket is the official digital lottery courier of the USA TODAY Network. Gannett may earn revenue for audience referrals to Jackpocket services. GAMBLING PROBLEM? CALL 1-800-GAMBLER, Call 877-8-HOPENY/text HOPENY (467369) (NY). 18+ (19+ in NE, 21+ in AZ). Physically present where Jackpocket operates. Jackpocket is not affiliated with any State Lottery. Eligibility Restrictions apply. Void where prohibited. Terms: This results page was generated automatically using information from TinBu and a template written and reviewed by a USA Today editor. You can send feedback using this form. This article originally appeared on USA TODAY: Idaho Lottery results, winning numbers: Pick 3, Pick 4, more